Partnership will test Mustang’s MB-101 with a second-generation oncolytic HSV-1 virus for potential in treating brain cancer. Canadian biotech launched by CCAB to fight the same cancer.

More M&A may be in store in the contract development and manufacturing space, with the founder of India’s Strides group apparently open to divesting his holding in the UK-based Sterling Pharma Solutions, at least going by what some deal street insiders say.

The contract drug delivery industry is facing disruptive influences from an evolving client base, the increase in biologics manufacturing and specialty pharma needs. In Vivo speaks to Catalent’s vice president of strategy, Cornell Stamoran, about the evolution of the industry and the continuous search for efficiency.

In line with its midterm growth strategy, the medical arm of Japanese chemicals group Sekisui Chemical has acquired Veredus Laboratories, a Singapore-based specialist in rapid and affordable multiplex molecular diagnostic systems. The acquisition will further strengthen Sekisui's presence in China, a key territory for the group and one of the main markets for Veredus' products.